Tempus AI, Inc. $TEM Shares Bought by Bamco Inc. NY

Key Points

• Bamco Inc. NY boosted its stake in Tempus AI by 53.7% in Q3, buying an additional 92,007 shares to hold 263,250 shares (about 0.15%) valued at roughly $21.25 million per its latest 13F filing.
• Other large institutions also increased exposure—Vanguard now owns 9,441,607 shares (~$762.0M) and BNP Paribas raised its position 312.7% to 1,274,549 shares—bringing total hedge fund and institutional ownership to about 24.22%.
• Insiders have been net sellers, offloading 570,143 shares worth roughly $35.6 million in the past 90 days, although insiders still hold 26.27% of the company’s stock.

Bamco Inc. NY raised its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 53.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 263,250 shares of the company's stock after buying an additional 92,007 shares during the quarter. Bamco Inc. NY owned about 0.15% of Tempus AI worth $21,247,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of TEM. Vanguard Group Inc. grew its stake in Tempus AI by 22.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company's stock valued at $762,032,000 after acquiring an additional 1,706,837 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Tempus AI by 312.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company's stock worth $102,869,000 after purchasing an additional 965,730 shares in the last quarter. AQR Capital Management LLC purchased a new position in Tempus AI in the 2nd quarter worth approximately $54,020,000. Geode Capital Management LLC boosted its holdings in shares of Tempus AI by 411.4% during the 2nd quarter. Geode Capital Management LLC now owns 649,420 shares of the company's stock worth $41,264,000 after purchasing an additional 522,443 shares during the last quarter. Finally, First Trust Advisors LP boosted its holdings in shares of Tempus AI by 299.4% during the 3rd quarter. First Trust Advisors LP now owns 590,137 shares of the company's stock worth $47,630,000 after purchasing an additional 442,395 shares during the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Trading Up 0.9%

NASDAQ TEM opened at $49.98 on Monday. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The stock has a market capitalization of $8.93 billion, a P/E ratio of -35.45 and a beta of 5.29. The firm's 50-day moving average is $59.20 and its two-hundred day moving average is $71.69. Tempus AI, Inc. has a 12 month low of $36.22 and a 12 month high of $104.32.

Wall Street Analysts Forecast Growth

TEM has been the subject of several recent research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tempus AI in a report on Thursday, January 22nd. Robert W. Baird initiated coverage on Tempus AI in a research note on Tuesday, February 17th. They set an "outperform" rating and a $59.00 price objective on the stock. Needham & Company LLC restated a "buy" rating and issued a $75.00 target price on shares of Tempus AI in a report on Wednesday, March 11th. Mizuho initiated coverage on Tempus AI in a research note on Thursday, February 19th. They issued an "outperform" rating and a $100.00 target price for the company. Finally, JPMorgan Chase & Co. reduced their price target on Tempus AI from $80.00 to $60.00 and set a "neutral" rating on the stock in a report on Wednesday, February 25th. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Tempus AI currently has a consensus rating of "Moderate Buy" and a consensus target price of $78.62.

Insiders Place Their Bets

In other Tempus AI news, EVP Andrew Polovin sold 10,949 shares of the business's stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $60.31, for a total value of $660,334.19. Following the sale, the executive vice president owned 126,918 shares of the company's stock, valued at $7,654,424.58. The trade was a 7.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO James William Rogers sold 10,084 shares of the company's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $595,460.20. Following the transaction, the chief financial officer owned 101,166 shares in the company, valued at $5,973,852.30. This trade represents a 9.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 570,143 shares of company stock worth $35,595,055. Insiders own 26.27% of the company's stock.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.